MCRBSeres Therapeutics, Inc.

MCRB Stock Price, Valuation & Chart | Seres Therapeutics, Inc.

Compare

$5.540+0.36 (+6.95%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology MCRB intrinsic value MCRB calculated fair value vs price

Overview Financials Dividends Ratios

MCRB Historical price chart

MCRB Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization53.65M

PE Ratio-2.16

EPS-2.56

Trading Volume63.65K

Today's High/Low5.6/5.17

Dividend Yield0.00

52 Week High/Low29.98/4.32

Shares Outstanding9.68M

MCRB Financial Statement

MCRB Analyst ratings

MCRB Analysis & performance metrics

MCRB Company profile

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and…

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile…

MCRB Management team

Name

Position

Eric D. Shaff M.B.A.CEO

President, Chief Executive Officer & Director

Kelly Brady

Senior Vice President of Clinical Development

Caroline Hensley

Assistant General Counsel

Dennis M. Walling M.D.

Senior Vice President of Clinical Development & Head of Clinical Research

Marella Thorell CPACFO

Executive Vice President & Chief Financial Officer

Chris McChalicher

Senior Vice President of Manufacturing, Quality, and Process Development

Ann Kurowski

Senior Vice President of Regulatory Affairs

Thomas J. DesRosier Esq., J.D.

Chief Legal Officer, Executive Vice President & Secretary

Name

Position

Eric D. Shaff M.B.A.CEO

President, Chief Executive Officer & Director

Kelly Brady

Senior Vice President of Clinical Development

Caroline Hensley

Assistant General Counsel

Dennis M. Walling M.D.

Senior Vice President of Clinical Development & Head of Clinical Research

Marella Thorell CPACFO

Executive Vice President & Chief Financial Officer

Chris McChalicher

Senior Vice President of Manufacturing, Quality, and Process Development

Ann Kurowski

Senior Vice President of Regulatory Affairs

Thomas J. DesRosier Esq., J.D.

Chief Legal Officer, Executive Vice President & Secretary

Management Team

Eric D. Shaff M.B.A.CEO

President, Chief Executive Officer & Director

Kelly Brady

Senior Vice President of Clinical Development

Caroline Hensley

Assistant General Counsel

Dennis M. Walling M.D.

Senior Vice President of Clinical Development & Head of Clinical Research

Marella Thorell CPACFO

Executive Vice President & Chief Financial Officer

Chris McChalicher

Senior Vice President of Manufacturing, Quality, and Process Development

Ann Kurowski

Senior Vice President of Regulatory Affairs

Thomas J. DesRosier Esq., J.D.

Chief Legal Officer, Executive Vice President & Secretary

Management

Eric D. Shaff M.B.A.CEO

President, Chief Executive Officer & Director

Kelly Brady

Senior Vice President of Clinical Development

Caroline Hensley

Assistant General Counsel

Dennis M. Walling M.D.

Senior Vice President of Clinical Development & Head of Clinical Research

Marella Thorell CPACFO

Executive Vice President & Chief Financial Officer

Chris McChalicher

Senior Vice President of Manufacturing, Quality, and Process Development

Ann Kurowski

Senior Vice President of Regulatory Affairs

Thomas J. DesRosier Esq., J.D.

Chief Legal Officer, Executive Vice President & Secretary

Total 8 executives

MCRB Frequently asked questions

What is Seres Therapeutics, Inc. (MCRB) Stock Price?

Current stock price of Seres Therapeutics, Inc. (MCRB) stock is $5.540. The stock price is +6.95% higher in the session. The intraday range can be seen from this page. Volume of Seres Therapeutics, Inc. (MCRB) stock is 63.65K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Seres Therapeutics, Inc. (MCRB) stock price going up or down today?

The stock price of Seres Therapeutics, Inc. (MCRB) can change with earnings, company news, and overall market sentiment. Seres Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Seres Therapeutics, Inc. stock expensive at its current price?

Whether Seres Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for MCRB on this page is -2.16. EPS on this page is -2.56. Compare those figures with peers and growth expectations before deciding if the current Seres Therapeutics, Inc. price is justified.

How has the stock price of Seres Therapeutics, Inc. (MCRB) performed historically?

Historical performance for Seres Therapeutics, Inc. (MCRB) is shown on the price chart on this page. Review multi-period moves alongside volume to see how MCRB reacted to past earnings and market events.

Should I buy Seres Therapeutics, Inc. (MCRB) stock, at this price?

Buying Seres Therapeutics, Inc. (MCRB) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.